Vascular Cognitive Impairment No DementiaNCT06898931
Language Intervention Training for Cognitive Protection in High-risk Cardio-Cerebrovascular Elderly Population
A study testing Dialect Interpreting Training in people with Vascular Cognitive Impairment No Dementia, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.
Trial summary
The global population is aging rapidly, with the number of elderly people with dementia projected to rise sharply, posing significant challenges to quality of life and societal burden.Frequent language switching, such as in interpreting, enhances cognitive abilities by improving attention, flexibility, and… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Vascular Cognitive Impairment No Dementia
- What is being tested?
- Dialect Interpreting Training
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 15 Apr 2025to 20 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged ≥ 60 years
- High risk of stroke (with ≥ 3 of 8 stroke risk factors, including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke, or with transient ischemic attack)
- command of Hangzhou dialect
- Written informed consent available
- Willingness to complete all assessments and participate in follow-up
- Adequate Visual and auditory acuity to undergo neuropsychological testing
Who cannot join
- previously diagnosed dementia
- Suspected dementia after clinical assessment by study physician at screening visit
- Previous history of major head trauma and any intracranial surgery
- Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
- Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
- Severe loss of vision, hearing, or communicative ability
Show all 9Show fewer
- Patients presenting a malignant disease with life expectancy < 3 years
- Participation in an ongoing investigational drug study
- Any MRI contraindications
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Study of Language Intervention Training for Cognitive Protection in High-risk Cardio-Cerebrovascular Elderly Population
The global population is aging rapidly, with the number of elderly people with dementia projected to rise sharply, posing significant challenges to quality of life and societal burden.Frequent language switching, such as in interpreting, enhances cognitive abilities by improving attention, flexibility, and memory.Dialect-switching training, similar to interpreting, is a non-invasive method that shows potential for promoting cognitive health in the elderly but remains under-researched.This study aims to investigate the cognitive-enhancing effects of a dialect-switching training program on older adults with vascular risk factors through a six-month intervention.
Read the detailed description
The global population is aging rapidly, with those aged 65+ expected to reach 16% of the total population by 2050. Aging is linked to increased cognitive impairment risks, including dementia prevalence rates of 5%-10% among the elderly in developed countries. In China, the number of elderly with dementia is projected to soar from 7.4 million to 18 million by 2030 without intervention. This trend poses significant challenges to quality of life and societal burden.
Language experiences, particularly frequent switching between languages, enhance cognitive abilities. Interpreting, which demands high-intensity language switching, significantly improves cognitive control and memory. Interpreters' need for rapid language conversion and reliance on attention, flexibility, and inhibition contribute to their cognitive advantages.
Similar to interpreting, switching between dialects and standard language requires high-frequency, high-intensity language conversion. This non-invasive training method is suitable for promoting cognitive health in the elderly. However, its potential benefits for cognitive enhancement in this population remain underexplored.
This study aims to design a dialect-switching training program simulating interpreting and investigate its potential cognitive-enhancing effects through a six-month intervention in older adults with vascular risk factors.
- Being tested
- Dialect Interpreting Training
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dialect Interpreting TrainingBehavioural
The intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments.
| Study group | Role | What they receive |
|---|---|---|
| Rountine | No intervention | The control group will not receive any language intervention training and will maintain their usual daily routines. |
| Dialect Interpreting Training | Experimental | The intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments. Receives: Behavioral: Dialect Interpreting Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI)
Primary Outcome
Measured: 6 months
Secondary outcomes (46)
Changes in brain functional network efficiency assessed by resting state fMRI
long-term secondary outcome
Measured: 2 years
Changes in brain functional network activity intensity assessed by resting state fMRI
long-term secondary outcome
Measured: 2 years
Changes in brain functional network efficiency assessed by resting state fMRI
long-term secondary outcome
Measured: 5 years
Changes in brain functional network activity intensity assessed by resting state fMRI
long-term secondary outcome
Measured: 5 years
Changes in brain functional network efficiency assessed by resting state fMRI
short-term secondary outcome
Measured: 6 months
Changes in brain functional network activity intensity assessed by resting state fMRI
short-term secondary outcome
Measured: 6 months
Changes in brain functional network connectivity assessed by resting state fMRI
long-term secondary outcome
Measured: 2 years
Changes in brain functional network connectivity assessed by resting state fMRI
long-term secondary outcome
Measured: 5 years
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
short-term secondary outcome
Measured: 6 months
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Measured: 2 years
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Measured: 5 years
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
short-term secondary outcome
Measured: 6 months
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Measured: 2 years
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Measured: 5 years
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
short-term secondary outcome
Measured: 6 months
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Measured: 2 years
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Measured: 5 years
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
short-term secondary outcome
Measured: 6 months
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Measured: 2 years
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Measured: 5 years
Changes in white matter hyperintensity (WMH) assessed on MRI with T2-Fluid-Attenuated-Inversion-Recovery (FLAIR) sequence
short-term secondary outcome
Measured: 6 months
Changes in lacunes assessed on MRI with T2 FLAIR sequence
short-term secondary outcome
Measured: 6 months
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
short-term secondary outcome
Measured: 6 months
Changes in microbleeds assessed on MRI with Susceptibility Weighted Imaging (SWI) sequence sequence
short-term secondary outcome
Measured: 6 months
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
short-term secondary outcome
Measured: 6 months
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 2 years
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 5 years
Changes in lacunes assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 2 years
Changes in lacunes assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 5 years
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 2 years
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Measured: 5 years
Changes in microbleeds assessed on MRI with SWI sequence sequence
long-term secondary outcome
Measured: 2 years
Changes in microbleeds assessed on MRI with SWI sequence sequence
long-term secondary outcome
Measured: 5 years
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
long-term secondary outcome
Measured: 2 years
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
long-term secondary outcome
Measured: 5 years
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
short-term secondary outcome
Measured: 6 months
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
long-term secondary outcome
Measured: 2 years
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
long-term secondary outcome
Measured: 5 years
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
short-term secondary outcome
Measured: 6 months
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
long-term secondary outcome
Measured: 2 years
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
long-term secondary outcome
Measured: 5 years
Metabolite profiles in participants' faecal samples and serum samples
short-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
Measured: 6 months
Metabolite profiles in participants' faecal samples and serum samples
long-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
Measured: 2 years
Incidence of stroke event including ischemic and hemorrhagic stroke
short-term secondary outcome
Measured: 6 months
Incidence of stroke event including ischemic and hemorrhagic stroke
long-term secondary outcome
Measured: 2 years
Incidence of stroke event including ischemic and hemorrhagic stroke
long-term secondary outcome
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2025
- Study start15 Apr 2025 (estimated)
- Primary completion20 Apr 2026 (estimated)
- Study completion20 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular Cognitive Impairment No DementiaStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Lou, Second Affiliated Hospital, Zhejiang University, School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06898931
- Sponsor's protocol ID
- Boost
- Status last verified
- Mar 2025
- First submitted
- 20 Mar 2025
- Last updated
- 27 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Language Intervention Training for Cognitive Protection in High-risk Cardio-Cerebrovascular Elderly Population
- ClinicalTrials.gov ID
- NCT06898931
- Acronym / sponsor ID
- Boost
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- 15 Apr 2025 (estimated)
- Primary completion
- 20 Apr 2026 (estimated)
- Study completion
- 20 Sep 2026 (estimated)
- First posted
- 27 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The global population is aging rapidly, with the number of elderly people with dementia projected to rise sharply, posing significant challenges to quality of life and societal burden.Frequent language switching, such as in interpreting, enhances cognitive abilities by improving attention, flexibility, and memory.Dialect-switching training, similar to interpreting, is a non-invasive method that shows potential for promoting cognitive health in the elderly but remains under-researched.This study aims to investigate the cognitive-enhancing effects of a dialect-switching training program on older adults with vascular risk factors through a six-month intervention.
Detailed description
The global population is aging rapidly, with those aged 65+ expected to reach 16% of the total population by 2050. Aging is linked to increased cognitive impairment risks, including dementia prevalence rates of 5%-10% among the elderly in developed countries. In China, the number of elderly with dementia is projected to soar from 7.4 million to 18 million by 2030 without intervention. This trend poses significant challenges to quality of life and societal burden.
Language experiences, particularly frequent switching between languages, enhance cognitive abilities. Interpreting, which demands high-intensity language switching, significantly improves cognitive control and memory. Interpreters' need for rapid language conversion and reliance on attention, flexibility, and inhibition contribute to their cognitive advantages.
Similar to interpreting, switching between dialects and standard language requires high-frequency, high-intensity language conversion. This non-invasive training method is suitable for promoting cognitive health in the elderly. However, its potential benefits for cognitive enhancement in this population remain underexplored.
This study aims to design a dialect-switching training program simulating interpreting and investigate its potential cognitive-enhancing effects through a six-month intervention in older adults with vascular risk factors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rountine | No intervention | –The control group will not receive any language intervention training and will maintain their usual daily routines. |
| Dialect Interpreting Training | Experimental | Behavioral: Dialect Interpreting TrainingThe intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients aged ≥ 60 years
- High risk of stroke (with ≥ 3 of 8 stroke risk factors, including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke, or with transient ischemic attack)
- command of Hangzhou dialect
- Written informed consent available
- Willingness to complete all assessments and participate in follow-up
Key exclusion criteria (9 listed)
- previously diagnosed dementia
- Suspected dementia after clinical assessment by study physician at screening visit
- Previous history of major head trauma and any intracranial surgery
- Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
- Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dialect Interpreting TrainingThe intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments. | Behavioural | Dialect Interpreting Training |
Primary outcome
Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI)
Time frame: 6 months
Primary Outcome
46 secondary outcomes
Changes in brain functional network efficiency assessed by resting state fMRI
Time frame: 2 years
Changes in brain functional network activity intensity assessed by resting state fMRI
Time frame: 2 years
Changes in brain functional network efficiency assessed by resting state fMRI
Time frame: 5 years
Changes in brain functional network activity intensity assessed by resting state fMRI
Time frame: 5 years
Changes in brain functional network efficiency assessed by resting state fMRI
Time frame: 6 months
Changes in brain functional network activity intensity assessed by resting state fMRI
Time frame: 6 months
Changes in brain functional network connectivity assessed by resting state fMRI
Time frame: 2 years
Changes in brain functional network connectivity assessed by resting state fMRI
Time frame: 5 years
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 6 months
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 2 years
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 5 years
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 6 months
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 2 years
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time frame: 5 years
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 6 months
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 2 years
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 5 years
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 6 months
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 2 years
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time frame: 5 years
Changes in white matter hyperintensity (WMH) assessed on MRI with T2-Fluid-Attenuated-Inversion-Recovery (FLAIR) sequence
Time frame: 6 months
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time frame: 6 months
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time frame: 6 months
Changes in microbleeds assessed on MRI with Susceptibility Weighted Imaging (SWI) sequence sequence
Time frame: 6 months
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time frame: 6 months
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
Time frame: 2 years
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
Time frame: 5 years
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time frame: 2 years
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time frame: 5 years
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time frame: 2 years
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time frame: 5 years
Changes in microbleeds assessed on MRI with SWI sequence sequence
Time frame: 2 years
Changes in microbleeds assessed on MRI with SWI sequence sequence
Time frame: 5 years
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time frame: 2 years
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time frame: 5 years
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time frame: 6 months
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time frame: 2 years
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time frame: 5 years
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
Time frame: 6 months
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Vascular Cognitive Impairment No Dementia
Recruiting
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
Cerebrovascular Disorders
Recruiting
Exercise as a Primer for Brain Stimulation in Vascular Cognitive Impairment No Dementia (VCIND)
Vascular Cognitive Impairment, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Dialect Interpreting Training in people with Vascular Cognitive Impairment No Dementia, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Min Lou, PhD, MD (057187783777, lm99@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2025.